drugset / Trial / NCT03399435

A Study in Healthy Male Volunteers to Investigate the Safety and Tolerability of a Single Dose of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine) for Brachial Plexus Blockade

NCT03399435

Phase 1 Terminated 242 enrolled Grünenthal GmbH
RandomizedParallel-groupTriple-blindOther

Summary

Neosaxitoxin is a new compound that is in clinical development as local anesthetic for surgical anesthesia and postoperative analgesia. The primary objective of this study is to evaluate the systemic and local safety and tolerability of ascending doses of neosaxitoxin alone and in combination with fixed doses of bupivacaine (with and without epinephrine), following brachial plexus blockade in healthy male subjects. Secondary objectives: * Evaluate the pharmacodynamics (PD) of ascending doses of neosaxitoxin, alone and in combination with fixed doses of bupivacaine (with and without epinephrine), following brachial plexus blockade. * Characterize the pharmacokinetics (PK) of neosaxitoxin and bupivacaine after brachial plexus blockade with neosaxitoxin alone or different drug combinations: neosaxitoxin and epinephrine, neosaxitoxin and bupivacaine, or neosaxitoxin and bupivacaine and epinephrine.

Timeline

Start
2018-01-30
Primary completion
2018-09-21
Completion
2018-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 10 mg Other
Subject Bupivacaine Other / unclassified 40 mg Other
Subject Bupivacaine Other / unclassified 80 mg Other
Subject Bupivacaine Other / unclassified 100 mg Other
Subject Epinephrine Other / unclassified 100 ug Other
Subject Neosaxitoxin Small molecule 1.25 ug Other
Subject Neosaxitoxin Small molecule 60 ug Other

Indications

No indication recorded.